For the first time, a therapy has been found that can delay
progression of metastatic uveal melanoma, a rare and deadly form of melanoma of
the eye. Results from a multicenter clinical trial show that a new drug called
selumetinib increases progression-free survival, the length of time during and
after treatment that a patient with metastases lives with the disease without
it progressing. The findings were published in the online edition of JAMA, the
Journal of the American Medical Association.